-
1 Comment
Checkpoint Therapeutics, Inc is currently in a long term downtrend where the price is trading 0.9% below its 200 day moving average.
From a valuation standpoint, the stock is 87.5% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 167.1.
Checkpoint Therapeutics, Inc's total revenue rose by 8.0% to $27K since the same quarter in the previous year.
Its net income has dropped by 15.9% to $-10M since the same quarter in the previous year.
Finally, its free cash flow fell by 4.3% to $-5M since the same quarter in the previous year.
Based on the above factors, Checkpoint Therapeutics, Inc gets an overall score of 2/5.
| Exchange | NASDAQ |
|---|---|
| CurrencyCode | USD |
| ISIN | US1628281073 |
| Sector | Healthcare |
| Industry | Biotechnology |
| Target Price | 4.3333 |
|---|---|
| Beta | 1.22 |
| Market Cap | 338M |
| PE Ratio | None |
| Dividend Yield | None |
Checkpoint Therapeutics, Inc., a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors. It is developing Olafertinib, which is in Phase 3 clinical trials for the treatment of adult patients with metastatic non-small cell lung cancer; CK-103 for the treatment of various advanced and metastatic solid tumor cancers; and Anti-Carbonic Anhydrase IX (CAIX) antibody, a product candidate in preclinical trials to recognize CAIX expressing cells and kill them via antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. The company has licensing and collaboration agreements with Adimab, LLC for the development of Cosibelimab; NeuPharma, Inc., to develop and commercialize Olafertinib; and Jubilant Biosys Limited for the development and commercialization of novel compounds that inhibit BET bromodomains, as well as collaboration with GC Cell. The company was incorporated in 2014 and is based in Waltham, Massachusetts.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for CKPT using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
